HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug
نویسندگان
چکیده
منابع مشابه
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
PURPOSE This article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of resistance, and ongoing studies evaluating this novel agent. BACKGROUND The development of HER2-targeted therapies has dramatically improved clinical outcomes for patients with ...
متن کاملHER2-Positive Breast Cancer
• Objective: To review the diagnosis and management of HER2-positive breast cancer. • Methods: Qualitative review of the literature. • Results: Amplification of HER2 occurs in 20% to 25% of breast cancers and is associated with highgrade tumors that are poorly differentiated and have higher rates of recurrence. Trastuzumab, a recombinant humanized monoclonal antibody against the extracellular d...
متن کاملTargeting alternative pathways in HER2-positive breast cancer.
Trastuzumab (Herceptin) has dramatically changed the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A phase III trial of firstline trastuzumab with various chemotherapy regimens compared with chemotherapy alone demonstrated a significant improvement in survival (25.1 vs 20.3 months) and overall response (50% vs 32%).1 This study resulted in the approval of ...
متن کاملCurrent and Emerging Treatment Regimens for HER2-Positive Breast Cancer.
Overexpression of human epidermal growth factor receptor 2 (HER2) is an important factor in cancer survival, proliferation, and metastasis. Agents that target HER2-positive tumors are used with traditional chemotherapies, with other targeted therapies, or as monotherapy to treat metastatic breast cancers.
متن کاملNeoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
Approximately 20%-25% of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, resulting in an overexpression of the HER2 receptor. This overexpression is associated with aggressive disease, relatively poor prognosis, and worse clinical outcomes. Neoadjuvant therapy is the standard treatment in patients with locally advanced, inflammatory, or ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nanomedicine: Nanotechnology, Biology and Medicine
سال: 2017
ISSN: 1549-9634
DOI: 10.1016/j.nano.2016.07.013